CMND Clearmind Medicine Inc. IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1892500 · Fiscal year ends 10/31
Financial factors as of 2026-01-31 (2026Q1), TTM = sum of the last four quarters
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-10-31 · USD | FY2024*2024-10-31 · USD | FY2023*2023-10-31 · USD | FY2022*2022-10-31 · CAD | FY2021*2021-10-31 · CAD |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $2.06M | $1.38M | $1.54M | 4.21M | 646,487 |
| SG&A expense | $3.61M | $4.36M | $4.76M | 4.33M | 3.03M |
| Operating income | — | — | — | -8.53M | -3.68M |
| Interest expense | $3,857 | $5,386 | — | 19,678 | 33,528 |
| Pretax income | -$3.79M | -$4.88M | -$8.60M | -9.37M | -3.72M |
| Income tax | $70,445 | $377,966 | $17,372 | 40,754 | — |
| Net income | -$3.86M | -$5.25M | -$8.62M | -9.41M | -3.72M |
| EPS (basic) | -30.35 | -67.80 | -1,703.04 | -7.24 | -4.01 |
| EPS (diluted) | -30.35 | -67.80 | -1,703.04 | -7.24 | -4.01 |
| Weighted avg. shares (diluted) | 127,093 | 77,503 | 5,062 | 43,335 | 30,911 |
| Balance sheet | |||||
| Cash & equivalents | $3.92M | $6.57M | $5.43M | 175,768 | 4.60M |
| Short-term investments | $1.66M | $289,388 | $86,112 | — | — |
| Receivables | — | — | — | 69,518 | 160,866 |
| Current assets | $5.95M | $7.09M | $5.79M | 593,312 | 4.92M |
| PP&E, netmay include right-of-use assets (IFRS) | — | — | $1,727 | 17,610 | 20,578 |
| Intangibles | $97,372 | $108,326 | $119,310 | 177,797 | 198,039 |
| Total assets | $6.08M | $7.26M | $5.95M | 1.13M | 5.16M |
| Current liabilities | $4.89M | $4.13M | $4.97M | — | — |
| Total liabilities | $4.89M | $4.15M | $4.97M | 2.64M | 357,155 |
| Shareholders' equity | $1.19M | $3.11M | $983,472 | -$1.11MUSD | 4.80M |
| Shares outstanding | — | — | — | 43,992 | 1.25M |
| Cash flow statement | |||||
| Operating cash flow | -$4.73M | -$4.86M | -$6.30M | -5.08M | -2.84M |
| Capital expenditure | — | — | — | 7,593 | 23,150 |
| Free cash flow | — | — | — | -5.09M | -2.86M |
| Investing cash flow | -$542,017 | -$238,097 | -$26,228 | -7,593 | -251,189 |
| Financing cash flow | $2.62M | $6.25M | $11.66M | 698,403 | 7.36M |
| Stock-based compensation | $805,890 | $998,918 | $834,813 | 788,657 | 692,155 |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.